Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
87 hedge funds and large institutions have $567M invested in Blueprint Medicines in 2016 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 27 reducing their positions, and 12 closing their positions.
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
44% more capital invested
Capital invested by funds: $395M → $567M (+$172M)
6% more funds holding
Funds holding: 82 → 87 (+5)
7% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 27
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
54% less call options, than puts
Call options by funds: $425K | Put options by funds: $921K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$20.3M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$13.3M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$7.6M |
| 4 |
DM
Deerfield Management
New York
|
+$5.36M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$27.2M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$9.68M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.01M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$4.33M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.88M |
BPMC Hedge Fund Activity: Q3 2016 in Review
87 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2016, worth a combined $567M — up 44% from $395M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new BPMC positions and 12 closed out — a net gain of 6 holders — while 29 added to existing stakes and 27 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $20.3M. The largest seller was PFM Health Sciences, cutting an estimated $27.2M.
- 87 institutional investors held Blueprint Medicines (BPMC) as of Q3 2016, up from 82 in Q2 2016.
- Funds reported $567M of Blueprint Medicines stock for Q3 2016, up 44% quarter-over-quarter.
- 18 funds opened new Blueprint Medicines positions in Q3 2016 and 12 closed out, a net change of +6 holders.
- The largest Blueprint Medicines buyer in Q3 2016 was Victory Capital Management, an estimated $20.3M added.
- The largest Blueprint Medicines seller in Q3 2016 was PFM Health Sciences, an estimated $27.2M sold.
Based on aggregated 13F filings for Q3 2016.